ALLERGIC REACTION UPON INTRAVITREAL ADMINISTRATION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
To describe the patient's allergic response to anti–vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization.Methods:
Clinical case report.Results:
Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept.Conclusion:
Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.